Mitotane: Adrenolytic Agent for Adrenocortical Carcinoma
Mitotane (o,p’-DDD) is an adrenolytic drug that causes selective destruction of adrenocortical cells by accumulating in mitochondria and disrupting steroidogenesis. It is the only approved drug specifically indicated for the treatment of adrenocortical carcinoma. Mitotane also suppresses cortisol production, making it useful in managing Cushing’s syndrome associated with adrenal tumors.
Product Profile
| CAS Number | 53-19-0 |
|---|---|
| Molecular Formula | C14H10Cl4 |
| Appearance | White to off-white crystalline powder |
| Therapeutic Category | Antineoplastic / Adrenolytic |
| Storage | Store at controlled room temperature, protect from light |
Applications
Mitotane is administered orally for the treatment of inoperable, recurrent, or metastatic adrenocortical carcinoma. Therapeutic drug monitoring is essential, as plasma concentrations between 14 and 20 mg/L are associated with clinical response. Due to its adrenolytic effect, patients require concomitant glucocorticoid replacement therapy. The drug has a long half-life and accumulates in adipose tissue, resulting in a prolonged period to reach steady state. Mitotane is also used off-label in veterinary medicine for the management of hyperadrenocorticism (Cushing’s disease) in dogs.
Why Source from TCS
TCS supplies mitotane to pharmaceutical companies across Europe and globally. Flexible order quantities from development samples to commercial volumes. Contact us with your target market and project requirements for a tailored quotation.
FAQ
What information should be included in an inquiry for Mitotane 53-19-0?
A useful inquiry normally includes the product name, target application, estimated quantity, destination market, and any specific documentation or packaging requests.
How is Mitotane 53-19-0 usually evaluated for sourcing?
This product is positioned for pharmaceutical sourcing discussions covering development, pilot, or commercial demand, subject to the buyer confirming application scope, market, and document requirements.
What documentation and commercial points are commonly reviewed before buying Mitotane 53-19-0?
For pharmaceutical API procurement, buyers commonly align on specification review, target market, batch or annual demand, packaging expectations, and the documentation package needed for the project.
Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.